Boehringer's survodutide cuts weight 13.1% in Phase III SYNCHRONIZE-2
The dual glucagon/GLP-1 agonist met both co-primary endpoints at 76 weeks in people with obesity or overweight plus type 2 diabetes, with glycemic control also improving.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 2 02:53 ETSource: The Clinical Trial Vanguard
The wire
- 01Boehringer Ingelheim reported 13.1% mean body weight loss over 76 weeks, meeting co-primary endpoints on weight change and the share of patients losing at least 5%, on both estimands.
- 02The population had type 2 diabetes, which typically blunts weight loss, but the figure still sits below semaglutide's 14.9% in STEP 1 and tirzepatide's up to 22.5% in SURMOUNT-1.
- 03Full data are not yet reported; the proportion reaching 10% or greater weight loss, and whether glucagon receptor activity differentiates safety, remain open ahead of a regulatory submission.
From the source
Read at clinicaltrialvanguard.comSurvodutide delivers 13.1% weight loss in Phase III trial for obesity and type 2 diabetes
Survodutide delivered 13.1% mean body weight loss over 76 weeks in the Phase III SYNCHRONIZE-2 trial, Boehringer Ingelheim announced Thursday, with results landing in a class where the weight-loss ceiling keeps rising. That number matters less as an absolute and more as a positioning problem: semaglutide produced 14.9% weight loss in 68 weeks in STEP 1 , and tirzepatide hit up to 22.5% over 72 wee
